|
|
BY OUR PHARMA CORRESPONDENT
2 September, 2005: The regulatory authorities in the Netherlands have approved Schering AG's new oral contraceptive Yasminelle. The Netherlands will serve as the Reference Member State for the upcoming Mutual Recognition Procedure to gain European wide marketing approval, an official release from Schering AG said.
Yasminelle contains 20 micrograms ethinyl estradiol and three milligrams drospirenone in a 21-day active pill intake regimen. The drug is similar to Schering’s oral contraceptive Yasmin but offers a lower estrogen dose with the unique progestin, drospirenone.
Yasminelle will build upon the success of Yasmin, which is the number one oral contraceptive worldwide. This new low-dose oral contraceptive with the well known pharmacodynamic profile of drospirenone will be offered soon to European women, the release stated.
Drospirenone exhibits antimineralocorticoid and antiandrogenic properties, unlike any other progestin available in oral contraceptives.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline.
BY OUR PHARMA CORRESPONDENT
|
